Nicole Gonzales
Concepts (309)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebral Hemorrhage | 27 | 2024 | 120 | 4.300 |
Why?
| | Stroke | 39 | 2025 | 1260 | 3.310 |
Why?
| | Neurology | 6 | 2026 | 114 | 2.400 |
Why?
| | Tissue Plasminogen Activator | 23 | 2024 | 244 | 2.050 |
Why?
| | Brain Ischemia | 19 | 2025 | 358 | 1.710 |
Why?
| | Fibrinolytic Agents | 17 | 2024 | 293 | 1.540 |
Why?
| | Thrombolytic Therapy | 14 | 2024 | 163 | 1.400 |
Why?
| | Sexism | 1 | 2024 | 70 | 0.790 |
Why?
| | Hematoma | 6 | 2015 | 59 | 0.770 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 71 | 0.750 |
Why?
| | Endarterectomy, Carotid | 4 | 2015 | 60 | 0.690 |
Why?
| | Education, Medical | 1 | 2024 | 276 | 0.650 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2022 | 498 | 0.640 |
Why?
| | Carotid Stenosis | 4 | 2014 | 102 | 0.630 |
Why?
| | Women | 1 | 2020 | 50 | 0.630 |
Why?
| | Decompressive Craniectomy | 1 | 2019 | 9 | 0.610 |
Why?
| | Medicine | 1 | 2020 | 125 | 0.570 |
Why?
| | Matrix Metalloproteinases | 1 | 2019 | 98 | 0.560 |
Why?
| | Time-to-Treatment | 2 | 2021 | 245 | 0.550 |
Why?
| | Stents | 5 | 2015 | 557 | 0.540 |
Why?
| | Mobile Health Units | 3 | 2024 | 20 | 0.520 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2022 | 547 | 0.500 |
Why?
| | Angioplasty | 2 | 2014 | 50 | 0.490 |
Why?
| | Attention | 1 | 2020 | 458 | 0.490 |
Why?
| | Brain Injuries | 1 | 2020 | 508 | 0.430 |
Why?
| | Cerebral Revascularization | 1 | 2014 | 22 | 0.430 |
Why?
| | Aged | 39 | 2024 | 26001 | 0.400 |
Why?
| | Emergency Medical Services | 5 | 2024 | 697 | 0.400 |
Why?
| | Humans | 70 | 2026 | 145307 | 0.400 |
Why?
| | Diffusion Tensor Imaging | 2 | 2024 | 73 | 0.390 |
Why?
| | Treatment Outcome | 28 | 2023 | 11731 | 0.380 |
Why?
| | Middle Aged | 42 | 2025 | 36021 | 0.380 |
Why?
| | Cerebral Ventricles | 3 | 2024 | 54 | 0.380 |
Why?
| | Hypertension | 3 | 2016 | 1266 | 0.360 |
Why?
| | Thiazolidinediones | 2 | 2012 | 139 | 0.350 |
Why?
| | Female | 48 | 2026 | 78605 | 0.320 |
Why?
| | Health Education | 4 | 2023 | 358 | 0.310 |
Why?
| | Male | 49 | 2025 | 72629 | 0.310 |
Why?
| | Disability Evaluation | 3 | 2021 | 310 | 0.300 |
Why?
| | Clinical Trials as Topic | 6 | 2023 | 1063 | 0.280 |
Why?
| | Prospective Studies | 14 | 2024 | 8011 | 0.280 |
Why?
| | Aged, 80 and over | 19 | 2024 | 8295 | 0.260 |
Why?
| | Schools | 2 | 2007 | 453 | 0.250 |
Why?
| | Time Factors | 12 | 2025 | 7186 | 0.240 |
Why?
| | Risk Factors | 10 | 2025 | 10816 | 0.230 |
Why?
| | Awareness | 1 | 2007 | 110 | 0.230 |
Why?
| | Demyelinating Autoimmune Diseases, CNS | 1 | 2005 | 4 | 0.230 |
Why?
| | Paraneoplastic Syndromes, Nervous System | 1 | 2005 | 14 | 0.230 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2005 | 11 | 0.230 |
Why?
| | Lactation | 1 | 2026 | 192 | 0.220 |
Why?
| | Cerebral Intraventricular Hemorrhage | 1 | 2024 | 4 | 0.220 |
Why?
| | Cerebral Blood Volume | 1 | 2024 | 5 | 0.220 |
Why?
| | Anticoagulants | 3 | 2019 | 726 | 0.210 |
Why?
| | Healthcare Disparities | 2 | 2024 | 736 | 0.200 |
Why?
| | Workplace | 1 | 2026 | 274 | 0.200 |
Why?
| | American Heart Association | 2 | 2023 | 356 | 0.200 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2003 | 17 | 0.200 |
Why?
| | Herpesvirus 2, Human | 1 | 2003 | 27 | 0.200 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2003 | 21 | 0.200 |
Why?
| | Pyramidal Tracts | 1 | 2023 | 30 | 0.190 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2022 | 26 | 0.190 |
Why?
| | Antihypertensive Agents | 3 | 2016 | 513 | 0.190 |
Why?
| | Ambulances | 2 | 2021 | 53 | 0.190 |
Why?
| | Pilot Projects | 5 | 2023 | 1894 | 0.180 |
Why?
| | Academic Medical Centers | 2 | 2024 | 548 | 0.180 |
Why?
| | Hypoglycemic Agents | 1 | 2012 | 1391 | 0.180 |
Why?
| | Heterozygote | 1 | 2022 | 315 | 0.180 |
Why?
| | Postoperative Complications | 1 | 2014 | 2938 | 0.180 |
Why?
| | Health Status Disparities | 1 | 2025 | 322 | 0.180 |
Why?
| | PPAR gamma | 3 | 2014 | 177 | 0.170 |
Why?
| | Databases, Factual | 3 | 2019 | 1488 | 0.170 |
Why?
| | Adult | 19 | 2025 | 40627 | 0.170 |
Why?
| | Prognosis | 6 | 2025 | 4310 | 0.170 |
Why?
| | Retrospective Studies | 16 | 2025 | 17149 | 0.170 |
Why?
| | Neuroprotective Agents | 2 | 2015 | 143 | 0.170 |
Why?
| | Health Promotion | 2 | 2007 | 777 | 0.170 |
Why?
| | Faculty, Medical | 1 | 2024 | 303 | 0.160 |
Why?
| | Sex Factors | 4 | 2025 | 2115 | 0.160 |
Why?
| | Anxiety Disorders | 1 | 2023 | 373 | 0.160 |
Why?
| | United States | 10 | 2024 | 16051 | 0.150 |
Why?
| | Factor VIIa | 2 | 2011 | 43 | 0.150 |
Why?
| | Pipecolic Acids | 2 | 2012 | 24 | 0.150 |
Why?
| | Aspirin | 1 | 2022 | 401 | 0.150 |
Why?
| | Schools, Medical | 1 | 2020 | 157 | 0.150 |
Why?
| | Inpatients | 1 | 2024 | 551 | 0.150 |
Why?
| | Predictive Value of Tests | 4 | 2019 | 2118 | 0.150 |
Why?
| | Recovery of Function | 3 | 2019 | 714 | 0.140 |
Why?
| | Overweight | 1 | 2023 | 610 | 0.140 |
Why?
| | Edema | 1 | 2019 | 124 | 0.140 |
Why?
| | Isoenzymes | 1 | 2019 | 299 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 281 | 0.140 |
Why?
| | Glasgow Coma Scale | 1 | 2019 | 221 | 0.140 |
Why?
| | Adenocarcinoma | 1 | 2005 | 931 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2012 | 2032 | 0.130 |
Why?
| | Disease Progression | 3 | 2013 | 2855 | 0.130 |
Why?
| | Genotype | 1 | 2022 | 1845 | 0.130 |
Why?
| | Mexican Americans | 2 | 2009 | 119 | 0.130 |
Why?
| | NF-E2-Related Factor 2 | 2 | 2015 | 95 | 0.130 |
Why?
| | Propensity Score | 1 | 2019 | 370 | 0.130 |
Why?
| | Communication | 1 | 2024 | 973 | 0.130 |
Why?
| | Injury Severity Score | 1 | 2019 | 605 | 0.120 |
Why?
| | Hospital Mortality | 2 | 2019 | 1035 | 0.120 |
Why?
| | Platelet Transfusion | 1 | 2017 | 80 | 0.120 |
Why?
| | Severity of Illness Index | 8 | 2024 | 2926 | 0.120 |
Why?
| | Ultrasonography, Doppler, Transcranial | 3 | 2013 | 48 | 0.120 |
Why?
| | Decision Making | 1 | 2023 | 980 | 0.120 |
Why?
| | Anxiety | 1 | 2023 | 1113 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 4 | 2021 | 2745 | 0.110 |
Why?
| | Texas | 4 | 2013 | 278 | 0.110 |
Why?
| | Fumarates | 1 | 2015 | 10 | 0.110 |
Why?
| | Microglia | 2 | 2008 | 269 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2020 | 696 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 386 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 2 | 2011 | 475 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 380 | 0.110 |
Why?
| | Retinoid X Receptors | 1 | 2014 | 38 | 0.110 |
Why?
| | Antithrombins | 2 | 2013 | 70 | 0.110 |
Why?
| | Recombinant Proteins | 4 | 2011 | 1371 | 0.110 |
Why?
| | Blood Pressure | 3 | 2011 | 1771 | 0.110 |
Why?
| | Risk Assessment | 2 | 2025 | 3686 | 0.100 |
Why?
| | Intraoperative Complications | 1 | 2015 | 158 | 0.100 |
Why?
| | Cerebral Infarction | 1 | 2014 | 47 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2014 | 104 | 0.100 |
Why?
| | Single-Blind Method | 1 | 2014 | 319 | 0.100 |
Why?
| | Cohort Studies | 7 | 2022 | 5982 | 0.100 |
Why?
| | Odds Ratio | 3 | 2021 | 1077 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2017 | 5431 | 0.100 |
Why?
| | Perioperative Care | 1 | 2015 | 232 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 947 | 0.100 |
Why?
| | Quality Control | 1 | 2013 | 163 | 0.100 |
Why?
| | Registries | 3 | 2025 | 2398 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2371 | 0.090 |
Why?
| | Medical Records | 1 | 2013 | 190 | 0.090 |
Why?
| | Sulfonamides | 3 | 2012 | 581 | 0.090 |
Why?
| | Biomarkers | 2 | 2019 | 4284 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2005 | 2652 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2026 | 6079 | 0.090 |
Why?
| | Carotid Artery, Internal | 1 | 2011 | 45 | 0.090 |
Why?
| | Telemedicine | 2 | 2020 | 957 | 0.090 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2011 | 23 | 0.090 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2011 | 9 | 0.090 |
Why?
| | Celecoxib | 1 | 2011 | 41 | 0.090 |
Why?
| | Collagen Type IV | 1 | 2011 | 28 | 0.090 |
Why?
| | Neurosurgical Procedures | 1 | 2013 | 202 | 0.090 |
Why?
| | Exercise | 1 | 2023 | 2206 | 0.080 |
Why?
| | Nervous System Diseases | 1 | 2014 | 284 | 0.080 |
Why?
| | Brain Edema | 1 | 2011 | 62 | 0.080 |
Why?
| | Carotid Arteries | 1 | 2012 | 207 | 0.080 |
Why?
| | History, 20th Century | 1 | 2012 | 327 | 0.080 |
Why?
| | NF-kappa B | 1 | 2014 | 662 | 0.080 |
Why?
| | Universities | 1 | 2013 | 453 | 0.080 |
Why?
| | Injections, Intra-Arterial | 4 | 2013 | 26 | 0.080 |
Why?
| | Nephrology | 1 | 2011 | 60 | 0.080 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2009 | 26 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2012 | 2033 | 0.080 |
Why?
| | Treatment Failure | 2 | 2014 | 365 | 0.080 |
Why?
| | Heparin | 1 | 2011 | 244 | 0.070 |
Why?
| | Health Care Surveys | 1 | 2011 | 539 | 0.070 |
Why?
| | Resuscitation Orders | 1 | 2009 | 48 | 0.070 |
Why?
| | Research Design | 2 | 2013 | 1137 | 0.070 |
Why?
| | Hand Transplantation | 1 | 2008 | 9 | 0.070 |
Why?
| | Intracranial Thrombosis | 1 | 2008 | 19 | 0.070 |
Why?
| | Venous Thrombosis | 1 | 2011 | 195 | 0.070 |
Why?
| | Caffeine | 1 | 2009 | 74 | 0.070 |
Why?
| | Hand Injuries | 1 | 2008 | 33 | 0.070 |
Why?
| | Endovascular Procedures | 1 | 2013 | 385 | 0.070 |
Why?
| | Adolescent | 8 | 2025 | 22507 | 0.070 |
Why?
| | Neutrophils | 1 | 2014 | 1135 | 0.070 |
Why?
| | Embolism | 1 | 2008 | 48 | 0.070 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 96 | 0.070 |
Why?
| | Pyrazoles | 1 | 2011 | 510 | 0.060 |
Why?
| | Quality Improvement | 1 | 2016 | 1296 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1358 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2011 | 465 | 0.060 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2005 | 47 | 0.060 |
Why?
| | Organ Transplantation | 1 | 2008 | 248 | 0.060 |
Why?
| | Methylprednisolone | 1 | 2005 | 64 | 0.060 |
Why?
| | Emergency Treatment | 1 | 2006 | 124 | 0.050 |
Why?
| | Teaching | 1 | 2007 | 240 | 0.050 |
Why?
| | Heart Diseases | 1 | 2008 | 350 | 0.050 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 598 | 0.050 |
Why?
| | Paralysis | 1 | 2005 | 67 | 0.050 |
Why?
| | Brain Stem | 1 | 2005 | 96 | 0.050 |
Why?
| | Muscle Weakness | 1 | 2005 | 92 | 0.050 |
Why?
| | Phagocytosis | 3 | 2014 | 299 | 0.050 |
Why?
| | Injections, Intravenous | 3 | 2011 | 200 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2005 | 307 | 0.050 |
Why?
| | Program Development | 1 | 2007 | 370 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2024 | 122 | 0.050 |
Why?
| | Administration, Intravenous | 2 | 2017 | 170 | 0.050 |
Why?
| | Young Adult | 3 | 2025 | 14163 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2021 | 3613 | 0.050 |
Why?
| | Ethanol | 1 | 2009 | 627 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2005 | 154 | 0.050 |
Why?
| | Emergency Service, Hospital | 1 | 2016 | 2329 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 529 | 0.050 |
Why?
| | Peptides | 1 | 2009 | 999 | 0.050 |
Why?
| | Meningitis, Aseptic | 1 | 2003 | 13 | 0.050 |
Why?
| | Growth and Development | 1 | 2023 | 9 | 0.050 |
Why?
| | Principal Component Analysis | 1 | 2023 | 198 | 0.050 |
Why?
| | Hemorrhage | 2 | 2023 | 810 | 0.050 |
Why?
| | Spinal Cord | 1 | 2005 | 383 | 0.050 |
Why?
| | Headache | 1 | 2003 | 150 | 0.040 |
Why?
| | Catalase | 2 | 2014 | 130 | 0.040 |
Why?
| | Age Factors | 2 | 2025 | 3339 | 0.040 |
Why?
| | Acute Disease | 3 | 2011 | 1031 | 0.040 |
Why?
| | Students | 1 | 2007 | 663 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 639 | 0.040 |
Why?
| | Certification | 1 | 2023 | 121 | 0.040 |
Why?
| | Respiratory Insufficiency | 1 | 2005 | 328 | 0.040 |
Why?
| | Partial Thromboplastin Time | 2 | 2012 | 50 | 0.040 |
Why?
| | Brain | 1 | 2014 | 2945 | 0.040 |
Why?
| | Reperfusion | 2 | 2013 | 54 | 0.040 |
Why?
| | DNA, Viral | 1 | 2003 | 358 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 983 | 0.040 |
Why?
| | Macrophages | 1 | 2008 | 1514 | 0.040 |
Why?
| | Practice Guidelines as Topic | 3 | 2017 | 1568 | 0.040 |
Why?
| | Hospital Bed Capacity | 1 | 2020 | 28 | 0.040 |
Why?
| | Guideline Adherence | 2 | 2017 | 589 | 0.040 |
Why?
| | Health Care Rationing | 1 | 2020 | 60 | 0.040 |
Why?
| | Ethics, Medical | 1 | 2020 | 90 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2012 | 967 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 2 | 2015 | 2541 | 0.040 |
Why?
| | Health Resources | 1 | 2020 | 131 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2023 | 3888 | 0.040 |
Why?
| | Caregivers | 1 | 2007 | 1056 | 0.030 |
Why?
| | Logistic Models | 2 | 2017 | 2119 | 0.030 |
Why?
| | Incidence | 1 | 2025 | 2892 | 0.030 |
Why?
| | CD36 Antigens | 2 | 2008 | 32 | 0.030 |
Why?
| | Combined Modality Therapy | 2 | 2013 | 1268 | 0.030 |
Why?
| | Hospitals | 1 | 2023 | 733 | 0.030 |
Why?
| | Arginine | 2 | 2012 | 262 | 0.030 |
Why?
| | Autoantibodies | 1 | 2005 | 1510 | 0.030 |
Why?
| | Ventriculostomy | 1 | 2017 | 24 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 285 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 2012 | 1048 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 427 | 0.030 |
Why?
| | Rats | 2 | 2015 | 5616 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2023 | 2959 | 0.030 |
Why?
| | Dimethyl Fumarate | 1 | 2015 | 12 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2017 | 205 | 0.030 |
Why?
| | Disease Models, Animal | 3 | 2014 | 4580 | 0.030 |
Why?
| | Body Mass Index | 1 | 2023 | 2439 | 0.030 |
Why?
| | Neuroimmunomodulation | 1 | 2014 | 68 | 0.030 |
Why?
| | Perfusion Imaging | 1 | 2014 | 65 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 916 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1540 | 0.020 |
Why?
| | Biomedical Research | 1 | 2020 | 713 | 0.020 |
Why?
| | Sex Distribution | 1 | 2014 | 386 | 0.020 |
Why?
| | Animals | 5 | 2015 | 38180 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2012 | 21 | 0.020 |
Why?
| | Cerebral Veins | 1 | 2012 | 16 | 0.020 |
Why?
| | Erythrocytes | 2 | 2008 | 757 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2020 | 1104 | 0.020 |
Why?
| | Cerebral Arteries | 1 | 2012 | 58 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1698 | 0.020 |
Why?
| | Plasminogen Activators | 1 | 2011 | 7 | 0.020 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2011 | 36 | 0.020 |
Why?
| | Radiography | 1 | 2013 | 846 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 3197 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2015 | 6009 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1311 | 0.020 |
Why?
| | Magnetic Resonance Angiography | 1 | 2012 | 251 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3085 | 0.020 |
Why?
| | Length of Stay | 1 | 2015 | 1342 | 0.020 |
Why?
| | Buspirone | 1 | 2009 | 5 | 0.020 |
Why?
| | Meperidine | 1 | 2009 | 6 | 0.020 |
Why?
| | Shivering | 1 | 2009 | 5 | 0.020 |
Why?
| | Life Support Care | 1 | 2009 | 42 | 0.020 |
Why?
| | Adjuvants, Anesthesia | 1 | 2009 | 13 | 0.020 |
Why?
| | Microspheres | 1 | 2009 | 142 | 0.020 |
Why?
| | Mice | 3 | 2015 | 18397 | 0.020 |
Why?
| | Microcirculation | 1 | 2009 | 145 | 0.020 |
Why?
| | Brain Damage, Chronic | 1 | 2008 | 18 | 0.020 |
Why?
| | Anti-Anxiety Agents | 1 | 2009 | 47 | 0.020 |
Why?
| | Infusions, Intra-Arterial | 1 | 2008 | 61 | 0.020 |
Why?
| | Cerebral Angiography | 1 | 2008 | 119 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2015 | 3129 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2009 | 421 | 0.020 |
Why?
| | Behavior | 1 | 2008 | 91 | 0.020 |
Why?
| | Drug Combinations | 1 | 2009 | 392 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2008 | 423 | 0.020 |
Why?
| | Enzyme Activators | 1 | 2007 | 9 | 0.020 |
Why?
| | Cultural Competency | 1 | 2008 | 93 | 0.020 |
Why?
| | Prostaglandin D2 | 1 | 2007 | 22 | 0.020 |
Why?
| | Regression Analysis | 1 | 2009 | 1003 | 0.020 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2006 | 24 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2007 | 162 | 0.020 |
Why?
| | Deep Brain Stimulation | 1 | 2009 | 213 | 0.010 |
Why?
| | Graft Survival | 1 | 2008 | 528 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 336 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3419 | 0.010 |
Why?
| | Graft Rejection | 1 | 2008 | 542 | 0.010 |
Why?
| | Recurrence | 1 | 2008 | 1138 | 0.010 |
Why?
| | Urban Population | 1 | 2008 | 495 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2007 | 898 | 0.010 |
Why?
| | Self Efficacy | 1 | 2008 | 414 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2006 | 675 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2011 | 1211 | 0.010 |
Why?
| | Program Evaluation | 1 | 2007 | 949 | 0.010 |
Why?
| | Atrial Fibrillation | 1 | 2008 | 552 | 0.010 |
Why?
| | Curriculum | 1 | 2007 | 1072 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2430 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2007 | 4156 | 0.010 |
Why?
| | Cytokines | 1 | 2007 | 2066 | 0.010 |
Why?
| | Parents | 1 | 2007 | 1404 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1420 | 0.010 |
Why?
| | Neurons | 1 | 2007 | 1642 | 0.010 |
Why?
| | Child | 1 | 2007 | 22712 | 0.000 |
Why?
|
|
Gonzales's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|